Ocellis, Inc.

Ocellis is a start-up pharmaceutical company that has produced a novel drug called PA1 for the treatment of neurotrophic keratitis (NK). Ocellis is seeking investors to help bring this groundbreaking drug to market and change the lives of millions of people affected by this debilitating condition that can lead to blindness. We will proceed down the regulatory pathway pioneered by Oxervate™, the only drug approved for this disorder, but with a superior product. Furthermore, we expect our revolutionary drug to find many uses in other types of corneal, and even retinal, insults after FDA approval for the treatment of NK.